We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Insights into Pain Regulation and Therapy

By Biotechdaily staff writers
Posted on 21 Jul 2003
A study has shown that the cerebral cortex not only perceives pain but also modulates pain signals, partly through the inhibitory neurotransmitter GABA, suggesting a target for therapy. More...
The results were published in the July 17 issue of Nature.

Researchers focused on a small region of the cerebral cortex known as the rostral agranular insular cortex (RAIC), one of the cortical areas consistently activated by painful stimuli. Since GABA is prolific in RAIC, they reasoned that changing levels of GABA could show how RAIC might regulate pain. When they increased levels of GABA throughout RAIC in normal rats, the animals displayed a clear and consistent analgesia. When the increase was sustained by injecting a gene (GAD 67) into neuronal and glial cells that encodes an enzyme that synthesizes GABA, the analgesia lasted up to 10 days. That suggested that GABA works through neural mechanisms that do not down-regulate over time.

When the researchers blocked transmission of signals through the descending pain inhibitory system, which extends from the RAIC to the spinal cord, the analgesic effect was reversed, indicating that GABA works partly through this system to enhance the inhibition of neurons that incite pain. Finding that a large number of RAIC neurons expressing GABA-B receptors project to the amygdala, they explored GABA's role in this pathway. After GABA was increased in the RAIC, GABA-B-bearing RAIC neurons that projected to the amygdala were selectively disinhibited. As a result, the rats experienced pain. When the activation was reversed, the pain was abolished.

"This finding demonstrates that the change in pain level works through two separate systems, with opposite effects,” said senior author Peter O'Hara, Ph.D., associate professor of anatomy at the University of California, San Francisco (USA; www.ucsf.edu). "This dual effect is probably a defining feature of pain modulation, and we speculate that an imbalance in the cortical output is likely to underlie some chronic pain states.”




Related Links:
University of California, San Francisco

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Age-Based Genetic Testing May Miss Most Inherited Cancer Risk Variants

Inherited cancer risk can influence diagnosis, treatment planning, and family screening, yet current testing practices often depend on a patient’s age at diagnosis. Many patients undergo germline genetic... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.